APGN | Apexigen, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3551 - 0.3963
52 Week Range	0.3310 - 8.28
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	94,426
Average Volume	262,332
Shares Outstanding	24,861,900
Market Cap	9,574,318
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-22

Valuation
Profitability
Growth
Health
P/E Ratio	-0.23
Forward P/E Ratio	N/A
EPS	-1.71
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	11
Country	USA
Website	APGN

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

APGN's peers: ALLR, ATNF, BNTC, DARE, DRUG, EVAX, GOVX, MESO, PALI, PHGE, PHIO, PYPD, SNGX, TCBP, VTGN, VTVT, ERNA, ICU

*Chart delayed

Analyzing fundamentals for APGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see APGN Fundamentals page.

Watching at APGN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on APGN Technicals page.